Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Sohag University

Status: Not yet enrolling

Conditions: Hematological Malignancies

Treatments: Diagnostic Test: Flowcytometry on bone marrow aspiration

Study type: Observational

Funder types: Other

Identifiers

NCT06258629

soh-med-24-01-03MS

Details and patient eligibility

About

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Enrollment: 40 estimated patients

Sex: All

Ages: 1 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed cases of hematological malignancis.

Exclusion criteria

• Known cases of hematological malignancies and on treatment.

Trial design

40 participants in 3 patient groups

control group

Description:

Age and sex matched healthy control individuals

Treatment:

Diagnostic Test: Flowcytometry on bone marrow aspiration

Case group

Description:

Available number of patients with newly diagnosed as hematological malignancy

Treatment:

Diagnostic Test: Flowcytometry on bone marrow aspiration

Case group after 6 months

Description:

Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.

Treatment:

Diagnostic Test: Flowcytometry on bone marrow aspiration